{"id":461454,"date":"2026-03-03T23:03:16","date_gmt":"2026-03-03T22:03:16","guid":{"rendered":"https:\/\/medizinonline.com\/utilizing-pleiotropic-cardio-and-nephroprotective-effects-of-sglt-2-i-and-glp-1-ra\/"},"modified":"2026-01-28T14:08:09","modified_gmt":"2026-01-28T13:08:09","slug":"utilizing-pleiotropic-cardio-and-nephroprotective-effects-of-sglt-2-i-and-glp-1-ra","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/utilizing-pleiotropic-cardio-and-nephroprotective-effects-of-sglt-2-i-and-glp-1-ra\/","title":{"rendered":"Utilizing pleiotropic cardio- and nephroprotective effects of SGLT-2-i and GLP-1-RA"},"content":{"rendered":"\n

Type 2 diabetes is currently understood to be a multisystemic disease, with the prognosis being significantly influenced by cardiac and renal pathology. An early, multimodal therapeutic approach that goes beyond pure blood glucose control is therefore important. There is now empirical evidence that SGLT-2 inhibitors and GLP-1 receptor agonists offer cardio- and nephroprotective benefits, and recent studies have shown that synergistic effects can be achieved through their combined use. <\/strong><\/p>\n\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Log in here<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"

Type 2 diabetes is currently understood to be a multisystemic disease, with the prognosis being significantly influenced by cardiac and renal pathology. An early, multimodal therapeutic approach that goes beyond……... <\/p>\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Log in here<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":461455,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Type 2 diabetes - glycemic control and prevention of secondary diseases","footnotes":""},"category":[11359,11513,11384,11413,11548,11503],"tags":[88208,65608,15896,88207,18549,12042],"powerkit_post_featured":[],"class_list":["post-461454","post","type-post","status-publish","format-standard","has-post-thumbnail","category-cardiology","category-congress-reports","category-endocrinology-and-diabetology","category-nephrology","category-rx-en","category-studies","tag-consequential-diseases-cardioprotective","tag-glp-1-ra-en-2","tag-glycemic-control","tag-nephroprotective-2","tag-sglt-2-i-en","tag-type-2-diabetes","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-04-12 01:32:14","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":461290,"slug":"utiliser-les-effets-pleiotropiques-cardioprotecteurs-et-nephroprotecteurs-du-sglt-2-i-et-du-glp-1-ra","post_title":"Utiliser les effets pl\u00e9iotropiques cardioprotecteurs et n\u00e9phroprotecteurs du SGLT-2-i et du GLP-1-RA","href":"https:\/\/medizinonline.com\/fr\/utiliser-les-effets-pleiotropiques-cardioprotecteurs-et-nephroprotecteurs-du-sglt-2-i-et-du-glp-1-ra\/"},"it_IT":{"locale":"it_IT","id":461533,"slug":"sfruttare-gli-effetti-pleiotropici-cardio-e-nefroprotettivi-di-sglt-2-i-e-glp-1-ra","post_title":"Sfruttare gli effetti pleiotropici cardio- e nefroprotettivi di SGLT-2-i e GLP-1-RA","href":"https:\/\/medizinonline.com\/it\/sfruttare-gli-effetti-pleiotropici-cardio-e-nefroprotettivi-di-sglt-2-i-e-glp-1-ra\/"},"pt_PT":{"locale":"pt_PT","id":461530,"slug":"utilizacao-dos-efeitos-pleiotropicos-cardio-e-nefroprotectores-do-sglt-2-i-e-do-glp-1-ra","post_title":"Utiliza\u00e7\u00e3o dos efeitos pleiotr\u00f3picos cardio e nefroprotectores do SGLT-2-i e do GLP-1-RA","href":"https:\/\/medizinonline.com\/pt-pt\/utilizacao-dos-efeitos-pleiotropicos-cardio-e-nefroprotectores-do-sglt-2-i-e-do-glp-1-ra\/"},"es_ES":{"locale":"es_ES","id":461527,"slug":"utilizacion-de-los-efectos-pleiotropicos-cardioprotectores-y-nefroprotectores-de-sglt-2-i-y-glp-1-ra","post_title":"Utilizaci\u00f3n de los efectos pleiotr\u00f3picos cardioprotectores y nefroprotectores de SGLT-2-i y GLP-1-RA","href":"https:\/\/medizinonline.com\/es\/utilizacion-de-los-efectos-pleiotropicos-cardioprotectores-y-nefroprotectores-de-sglt-2-i-y-glp-1-ra\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/461454","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/comments?post=461454"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/461454\/revisions"}],"predecessor-version":[{"id":461456,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/461454\/revisions\/461456"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media\/461455"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media?parent=461454"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/category?post=461454"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/tags?post=461454"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/powerkit_post_featured?post=461454"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}